Selected abstracts of the 26th Annual Conference of the Anxiety Disorders Association of America, March 23–26, 2006, Miami, Florida

Abé, Tatsuya; Ishii, Akira

doi:10.1002/da.20335

Depress. Anxiety

2007

DOI: 10.1002/da.20335

|View full text |Cite

Selected abstracts of the 26th Annual Conference of the Anxiety Disorders Association of America, March 23–26, 2006, Miami, Florida

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2008

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine

Trivedi¹,

Desaiah²,

Ossanna³

et al. 2008

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Most antidepressants in clinical use are believed to function by enhancing neurotransmission of serotonin [5-hydroxytryptamine (5-HT)] and/or norepinephrine (NE) via inhibition of neurotransmitter reuptake. Agents that affect reuptake of both 5-HT and NE (serotonin-norepinephrine reuptake inhibitors) have been postulated to offer greater efficacy for the treatment of major depressive disorder (MDD). These dual-acting agents also display a broader spectrum of action, including efficacy for MDD and associated painful physical symptoms, diabetic peripheral neuropathic pain, generalized anxiety disorder, and fibromyalgia syndrome. Substantial preclinical evidence shows that duloxetine, an approved drug for the treatment of MDD, generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain, inhibits reuptake of both 5-HT and NE. This paper reviews clinical and neurochemical evidence of duloxetine's effects on 5-HT and NE reuptake inhibition. The clinical evidence supporting duloxetine's effects on NE reuptake inhibition includes indirect measures such as altered excretion of NE metabolites, cardiovascular effects, and treatment-emergent adverse event profiles similar to those for other drugs believed to act through the inhibition of NE reuptake. In summary, the data presented in this report provide clinical evidence of a mechanism for duloxetine involving both 5-HT and NE reuptake inhibition in humans and are consistent with preclinical evidence for 5-HT/NE reuptake inhibition.

show abstract

Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine

Trivedi¹,

Desaiah²,

Ossanna³

et al. 2008

International Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder

Sheehan

Meyers

Prakash

et al. 2008

Current Medical Research and Opinion

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Selected abstracts of the 26th Annual Conference of the Anxiety Disorders Association of America, March 23–26, 2006, Miami, Florida

Cited by 2 publications

References 47 publications

Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine

Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine

The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder

Contact Info

Product

Resources

About